Bone Pain in Myalgic Encephalomyelitis (ME)

Purpose

This document explains how bone pain can occur in Myalgic Encephalomyelitis (ME), outlining the possible underlying mechanisms and how it fits within the broader pattern of neuroimmune and metabolic dysfunction associated with the condition.

Key Points

1. Bone Pain as a Secondary Symptom

• Bone pain is not considered a primary diagnostic feature of ME.
• However, many individuals report deep, aching pain that feels distinct from muscle or joint pain.

2. Neuroinflammation and Pain Sensitisation

• ME involves dysfunction of the central nervous system.
• Increased sensitivity to pain signals may cause heightened perception of deep or bone-related pain.
• Pain may feel more intense and widespread than expected.

3. Immune Dysfunction and Inflammation

• Chronic immune activation is common in ME.
• Inflammatory signals can stimulate pain pathways, leading to deep, aching sensations often felt in bones or bone marrow areas.

4. Energy Dysfunction and Reduced Blood Flow

• Impaired energy production and circulation may affect tissues, including bones.
• Reduced oxygen delivery and metabolic stress can contribute to deep, persistent pain.

5. Co‑Occurring Conditions

• Bone pain may be influenced by overlapping conditions such as:
  • Fibromyalgia
  • Orthostatic intolerance
  • Reduced bone density from inactivity or nutritional factors
• These can contribute to limb heaviness, discomfort, and deeper pain sensations.

6. Patient-Reported Experiences

• Individuals often describe:
  • Deep, internal aching in areas such as legs, hips, ribs, or spine
  • Pain that feels different from muscle soreness
  • Worsening of pain after exertion
  • Night-time discomfort that disrupts sleep

7. Symptom Triggers and Patterns

• Bone pain may worsen with:
  • Post-exertional neuroimmune exhaustion (PEM/PENE)
  • Physical or cognitive overexertion
  • Illness or stress
• Symptoms can fluctuate in intensity over time.

8. Assessment and Management Considerations

• Severe or progressive bone pain should be evaluated clinically.
• Possible assessments may include:
  • Bone density testing
  • Nutritional and metabolic screening
  • Inflammatory markers
• Management often focuses on:
  • Pacing to avoid symptom flares
  • Appropriate pain management strategies
  • Treating any underlying contributing factors

Target Audience

• Individuals diagnosed with ME/CFS
• Caregivers and family members
• Healthcare professionals
• Researchers studying pain and neuroimmune dysfunction

Overall Outcome

The document highlights that bone pain, while not a defining hallmark of ME, is a recognised symptom in some individuals. It likely reflects the combined effects of neuroinflammation, immune activation, and impaired energy metabolism. Understanding this symptom within the broader context of ME helps support more effective symptom recognition, evaluation, and management.